Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q4 EPS of ($0.20), $0.12 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $151.67 million versus the consensus estimate of $143.78 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.